Key result
Nepal's comprehensive vaccine preventable diseases surveillance system had a total annual economic cost of USD 4.81 million (USD 0.18 per capita) and a financial cost of USD 4.38 million.
Why the study?
Assessing the cost of vaccine preventable diseases surveillance is critical amid GPEI funding transitions, but knowledge on national costs for multi-disease surveillance in countries like Nepal is limited.
Cross-Sectional
Yes
The annual economic cost of VPD surveillance in Nepal is USD 4.81 million, highlighting the need for strategic financing as polio program funding diminishes.
Nepal VPD surveillance cost data inform polio transition planning; leaves open optimal domestic-donor financing models for LMICs.
Assessing the cost of vaccine preventable diseases (VPD) surveillance is becoming more important in the context of the Global Polio Eradication Initiative (GPEI) funding transition, since GPEI support to polio surveillance helped the incremental building of VPD surveillance systems in many countries, including low income countries such as Nepal. However, there is limited knowledge on the cost of conducting VPD surveillance, especially the national cost for surveillance of multiple vaccine-preventable diseases. The current study sought to calculate the economic and financial costs of Nepal's comprehensive VPD surveillance systems from July 2016 to July 2017. At thecentral level, all surveillance units were included in the sample. At sub-national level, a purposive sampling strategy was used to select a representative sample from locations involved in conducting surveillance. The sub-national sample costs were extrapolated to the nationwide VPD surveillance system. Nepal's total annual economic cost of VPD surveillance was USD 4.81 million or USD 0.18 per capita, while the total financial cost was USD 4.38 million or USD 0.16 per capita. Government expenditures accounted for 56% of the total economic cost, and World Health Organization accounting for 44%. The biggest cost driver was personnel accounting for 51% of the total economic cost. WHO supported trained surveillance personnel through donor funding, mainly from Global Polio Eradication Initiative. As a polio transition priority country, Nepal will need to make strategic choices to fully self-finance or seek full donor support or a mixed-financing model as polio program funding diminishes.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2021) conducted a cross-sectional in Vaccine preventable diseases. Vaccine preventable diseases surveillance was evaluated on Total annual economic and financial cost. Nepal's comprehensive vaccine preventable diseases surveillance system had a total annual economic cost of USD 4.81 million (USD 0.18 per capita) and a financial cost of USD 4.38 million.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: